BRIEF-Verastem Oncology Announces FDA Acceptance And Priority Review Of New Drug Application For Avutometinib In Combination With Defactinib For The Treatment Of Recurrent Kras Mutant Low-Grade Serous Ovarian Cancer

Reuters
31 Dec 2024
BRIEF-<a href="https://laohu8.com/S/VSTM">Verastem</a> Oncology Announces FDA Acceptance And Priority Review Of New Drug Application For Avutometinib In Combination With Defactinib For The Treatment Of Recurrent Kras Mutant Low-Grade Serous Ovarian Cancer

Dec 30 (Reuters) - Verastem Inc VSTM.O:

  • VERASTEM ONCOLOGY ANNOUNCES FDA ACCEPTANCE AND PRIORITY REVIEW OF NEW DRUG APPLICATION FOR AVUTOMETINIB IN COMBINATION WITH DEFACTINIB FOR THE TREATMENT OF RECURRENT KRAS MUTANT LOW-GRADE SEROUS OVARIAN CANCER

  • VERASTEM INC - PDUFA TARGET ACTION DATE SET FOR JUNE 30, 2025

Source text: ID:nBwBJ6h5a

Further company coverage: VSTM.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10